DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Rating) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.

DBVT has been the topic of several other research reports. The Goldman Sachs Group lowered shares of DBV Technologies from a “neutral” rating to a “sell” rating in a research report on Friday, December 16th. Societe Generale raised shares of DBV Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, January 4th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $5.63.

DBV Technologies Price Performance

NASDAQ DBVT opened at $1.56 on Tuesday. The company has a 50 day simple moving average of $1.41 and a 200-day simple moving average of $1.87. The firm has a market capitalization of $293.71 million, a price-to-earnings ratio of -2.84 and a beta of 1.29. DBV Technologies has a 52-week low of $1.08 and a 52-week high of $3.43.

DBV Technologies (NASDAQ:DBVT – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.07. The business had revenue of $2.07 million during the quarter, compared to analyst estimates of $1.54 million. DBV Technologies had a negative net margin of 778.60% and a negative return on equity of 44.34%. On average, analysts predict that DBV Technologies will post -1.01 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its stake in shares of DBV Technologies by 16.5% in the first quarter. BlackRock Inc. now owns 687,341 shares of the company’s stock worth $1,093,000 after acquiring an additional 97,412 shares during the last quarter. ExodusPoint Capital Management LP acquired a new stake in DBV Technologies during the second quarter worth $352,000. BNP Paribas Arbitrage SNC boosted its stake in DBV Technologies by 203.3% during the third quarter. BNP Paribas Arbitrage SNC now owns 57,899 shares of the company’s stock worth $102,000 after buying an additional 38,812 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in DBV Technologies during the third quarter worth $67,000. Finally, Two Sigma Investments LP boosted its stake in DBV Technologies by 80.9% during the third quarter. Two Sigma Investments LP now owns 35,920 shares of the company’s stock worth $64,000 after buying an additional 16,066 shares in the last quarter. Institutional investors and hedge funds own 18.37% of the company’s stock.

DBV Technologies Company Profile

(Get Rating)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.